Search Result

Results for "

Glucagon-Like Peptide-1 Receptor (GLP-1R)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GLP Receptor (29) Arrestin (1) Drug Intermediate (1) GCGR (20) Insulin Receptor (1) Neuropeptide Y Receptor (1) Phosphodiesterase (PDE) (1) Reference Standards (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (2) Endocrinology (1) Inflammation/Immunology (10) Metabolic Disease (43) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Recombinant Proteins

Antibodies

Targets Recommended: GLP Receptor RXFP Receptor Formyl Peptide Receptor (FPR) Peptide-Drug Conjugates (PDCs) Natriuretic Peptide Receptor (NPR) Connective Peptide CGRP Receptor Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3506

Retatrutide 3 Publications Verification LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

HY-112185

Orforglipron 1 Publications Verification LY3502970; GLP-1 Receptor agonist 1	GCGR	Metabolic Disease Inflammation/Immunology
Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete .

HY-125824

Danuglipron 4 Publications Verification PF-06882961	GCGR	Metabolic Disease
Danuglipron (PF-06882961) is an orally active **glucagon-like peptide-1 receptor (GLP-1R)** agonist. Danuglipron has the potential for type 2 diabetes research .

HY-P3506A

Retatrutide TFA 3 Publications Verification LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

HY-160734

Aleniglipron GSBR-1290	GLP Receptor	Metabolic Disease
Aleniglipron (GSBR-1290) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist, with an EC₅₀ value of less than 0.1 nM in HDB cell lines in cAMP stimulation assays. Aleniglipron selectively activates the Gαs-cAMP signaling pathway of *GLP-1R* without β-arrestin recruitment. Aleniglipron induces insulin release, promotes glucose clearance, reduces food intake and decreases body weight. Aleniglipron is applicable to research related to type 2 diabetes and obesity .

HY-112185A

Orforglipron hemicalcium hydrate 1 Publications Verification LY3502970 hemicalcium hydrate; GLP-1 Receptor agonist 1 hemicalcium hydrate	GCGR	Metabolic Disease Inflammation/Immunology
Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) is the calcium salt hydrate form of Orforglipron (HY-112185). Orforglipron is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorating the type 2 diabete .

HY-177295

Naperiglipron LY3549492	GLP Receptor Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Naperiglipron (LY3549492) is an orally active **Glucagon-like peptide 1 receptor (GLP-1R) agonist with an EC₅₀** of 1.14 nM for hGLP-1R. Naperiglipron significantly decreases the level of blood glucose in GLP-1R knock-in mouse models. Naperiglipron inhibits PDE10A1 enzyme activity (IC₅₀: 7.43 μM) with a weak hERG inhibitory activity. Naperiglipron can be used for type II diabetes mellitus (T2DM) and obesity research .

HY-101116

GLP-1R Antagonist 1 5 Publications Verification	GCGR	Metabolic Disease
GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of **glucagon-like peptide 1 receptor (GLP-1R), with an IC₅₀** of 650 nM .

HY-112679

GLP-1 receptor agonist 2	GCGR	Inflammation/Immunology
GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor *(GLP-1R)* agonist .

HY-145458

PF-06954522 GLP-1 Receptor agonist 9	GLP Receptor	Metabolic Disease
PF-06954522 is a glucagon-like peptide-1 receptor (GLP-1R) agonist. PF-06954522 is applicable to research related to type 2 diabetes .

HY-142162

LSN3318839	GCGR	Metabolic Disease
LSN3318839 is an orally active positive modulator of the **glucagon-like peptide-1 receptor (GLP-1R)**. LSN3318839 can increase the secretion of insulin and has the effect of lowering blood sugar .

HY-P10929

Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH	Drug Intermediate	Others
Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH is a drug intermediate in the synthesis of Tirzepatide. Tirzepatide is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor (GLP-1R) agonist .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting **glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R)** dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-45894

tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu Semaglutide side chain	GLP Receptor	Metabolic Disease Inflammation/Immunology
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu is an intermediate in the synthesis of the glucagon-like peptide 1 receptor (GLP-1R) agonist Semaglutide (HY-114118). tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu exhibits a strong binding affinity to albumin and can be used to modify SN38 prodrugs to improve tumor distribution .

HY-145412

GLP-1 receptor agonist 7	GLP Receptor	Metabolic Disease
GLP-1 receptor agonist 7 (Compound 130b) is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 7 generates cAMP under the mediation of GLP-1R with an EC₅₀ of ≤ 0.2 nM. GLP-1 receptor agonist 7 can be used to study diseases related to the GLP-1 receptor (particularly type 2 diabetes) .

HY-P10018

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. Bamadutide improves post-meal blood glucose control by significantly enhancing β-cell function and slowing down the rate of glucose absorption in the body. Bamadutide can be used for the research of metabolic diseases such as type 2 diabetes .

HY-P990013

Gulgafafusp alfa Glutazumab; GMA-102; GMA-105	GCGR	Metabolic Disease
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor *GLP1R* .

HY-143312

V-0219	GLP Receptor	Metabolic Disease Inflammation/Immunology
V-0219 is an orally active glucagon-like peptide-1 receptor (GLP-1R) positive allosteric modulator. V-0219 potentiates *GLP-1R* stimulation, and enhances GLP-1-induced cAMP production and insulin secretion. V-0219 potentiates glucose-dependent insulin secretion. V-0219 improves glucose handling in normal and diabetic rodents. V-0219 can be used for the research of obesity-associated diabetes .

HY-P3506B

Retatrutide acetate LY3437943 acetate	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .

HY-143312A

V-0219 hydrochloride	GLP Receptor	Metabolic Disease Inflammation/Immunology
V-0219 hydrochloride is an orally active glucagon-like peptide-1 receptor (GLP-1R) positive allosteric modulator. V-0219 hydrochloride potentiates *GLP-1R* stimulation, and enhances GLP-1-induced cAMP production and insulin secretion. V-0219 hydrochloride potentiates glucose-dependent insulin secretion. V-0219 hydrochloride improves glucose handling in normal and diabetic rodents. V-0219 hydrochloride can be used for the research of obesity-associated diabetes .

HY-147625

GLP-1R agonist 12	GLP Receptor	Metabolic Disease
GLP-1R agonist 12 (Compound 123) is an agonist of **glucagon-like peptide-1 receptors (GLP-1R)*. GLP-1R* agonist 12 can be used for diabetes research .

HY-144035

GLP-1R agonist 4	GCGR	Metabolic Disease Inflammation/Immunology
GLP-1R agonist 4 is a **glucagon-like peptide-1** (GLP-1) *receptor* agonist. GLP-1 is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 4 can be used for the research of type 2 diabetes mellitus, obesity, non-alcoholic steatohepatitis, insulin resistance and etc .

HY-129657

GLP-1 receptor agonist 4	GCGR	Metabolic Disease
GLP-1 receptor agonist 4 is a **glucagon-like peptide-1 receptor (GLP-1R) agonist extracted from patent WO2009111700A2, compound 87, has an EC₅₀** of 64.5 nM. GLP-1 receptor agonist 4 can be used in the research for treatment of diabetes .

HY-125824A

Danuglipron tromethamine PF-06882961 tromethamine	GCGR	Metabolic Disease
Danuglipron (PF-06882961) tromethamine is an orally active **glucagon-like peptide-1 receptor (GLP-1R)** agonist. Danuglipron tromethamine has the potential for type 2 diabetes research .

HY-142162A

(S,R)-LSN3318839	GCGR	Metabolic Disease
(S,R)-LSN3318839 is the stereoisomer of LSN3318839 (HY-142162). LSN3318839 is an orally active positive modulator of the **glucagon-like peptide-1 receptor (GLP-1R)**. LSN3318839 can increase the secretion of insulin and has the effect of lowering blood sugar .

HY-P3539

Exendin-4 (3-39)	GCGR	Neurological Disease Endocrinology
Exendin-4 (3-39) is a *peptide. Exendin-4 (3-39) is a truncated form of Exendin-4 (HY-13443) that lacks the first two amino acids. Exendin-4 is a potent Glucagon-like* peptide-1 receptor (GLP-1r) agonist. Exendin-4 (3-39) and Exendin-4 can be used for the research of diabetic and hypothalamic-pituitary-adrenal (HPA) axis .

HY-162436

GLP-1R agonist 21	GLP Receptor	Metabolic Disease
GLP-1R agonist 21 (Compound I-134) is an agonist for glucagon-like peptide-1 receptor (GLP-1 *receptor), with EC₅₀* of 0.0104 nM .

HY-162435

GLP-1R agonist 20	GLP Receptor	Metabolic Disease
GLP-1R agonist 20 (Compound I-132) is an agonist for glucagon-like peptide-1 receptor (GLP-1 *receptor), with EC₅₀* of 0.0162 nM .

HY-162437

GLP-1R agonist 22	GLP Receptor	Metabolic Disease
GLP-1R agonist 22 (Compound I-135) is an agonist for glucagon-like peptide-1 receptor (GLP-1 *receptor), with EC₅₀* of 0.0165 nM .

HY-P10302

GLP-1R/GIPR agonist-1	GLP Receptor Insulin Receptor	Metabolic Disease
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for *GLP-1* (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones *GLP-1* and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-P11043

GEP44	GLP Receptor Neuropeptide Y Receptor Arrestin	Metabolic Disease
GEP44 is a peptide biased triple agonist targeting **Glucagon-like peptide 1 receptor (GLP-1R), neuropeptide Y1 Receptor (Y1-R), and neuropeptide Y2 Receptor (Y2-R)*. GEP44 induces Y1-R antagonist-controlled, GLP-1R-dependent stimulation of insulin secretion in both rat and human pancreatic islets by counteracting effects of Y1-R and GLP-1R* agonism. GEP44 promotes insulin-independent Y1-R-mediated glucose uptake in muscle tissue and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 can be used for obesity and type 2 diabetes mellitus research .

HY-176770

GLP-1R agonist 34	GLP Receptor	Metabolic Disease
GLP-1R agonist 34 (Compound 1) is an orally active small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1R agonist 34 promotes insulin secretion, inhibits glucagon release, and delays gastric emptying, thereby effectively lowering blood glucose levels. GLP-1R agonist 34 is promising for research of metabolic diseases, including type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-171850

GLP-1R modulator-1	GLP Receptor	Metabolic Disease Inflammation/Immunology
GLP-1R modulator-1 (Compound 384) is an orally active, potent selective glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1R modulator-1 activates G-protein coupled signaling, elevates intracellular cAMP levels, promotes insulin secretion, delays gastric emptying and suppresses appetite. GLP-1R modulator-1 is promising for research of type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-172673

GLP-1R agonist 31	GCGR	Metabolic Disease
GLP-1R agonist 31 (Compound 1) is an amorphous glucagon-like peptide-1 receptor (GLP-1R) agonist .

HY-P11262

GUB021794	GLP Receptor	Metabolic Disease
GUB021794 is a potent and highly selective glucagon-like peptide-1 receptor (GLP-1R) agonist developed using the streaMLine platform with an EC₅₀ value of 18 pM. GUB021794 has a very weak activity against SCTR, with an EC₅₀ value of 190 nM. GUB021794 can significantly reduce the body weight, food intake, and total fat mass of mice in a diet-induced obesity (DIO) model. GUB021794 can be used for research on obesity/diabetes .

HY-168585

GLP-1R agonist 26	GLP Receptor	Metabolic Disease
GLP-1R agonist 26 (compound 1) is a **glucagon-like peptide-1 receptor (GLP-1R) agonist with an EC₅₀** of <10 nM .

HY-162433

GLP-1R agonist 41	GLP Receptor	Metabolic Disease
GLP-1R agonist 41 is an agonist for glucagon-like peptide-1 receptor (GLP-1 *receptor), with EC₅₀* of 0.0187 nM .

HY-162434

GLP-1R agonist 42	GLP Receptor	Metabolic Disease
GLP-1R agonist 42 is an agonist for glucagon-like peptide-1 receptor (GLP-1 *receptor), with EC₅₀* of 0.0122 nM .

HY-P3542

Des His1, Glu8 Exendin-4	GCGR	Metabolic Disease
Des His1, Glu8 Exendin-4 is a potent **glucagon-like peptide-1 receptor (GLP-1-R)** antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal .

HY-P0165B

Taspoglutide acetate ITM077 acetate; R1583 acetate; BIM51077 acetate	GLP Receptor	Metabolic Disease
Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an K_i value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC₅₀ = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .

HY-182849

GLP-1R agonist 44	GLP Receptor	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
GLP-1R agonist 44 is a **glucagon-like peptide-1 receptor** (GLP-1R) agonist. GLP-1R agonist 44 can be used for the research of diseases related to GLP-1R, such as type 2 diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, nephropathy, gout, hematuria, cardiovascular disease .

HY-180489

GLP-1R agonist 38	GLP Receptor	Metabolic Disease
GLP-1R agonist 38 (page 15, compound 1) is a **glucagon-like peptide-1 receptor (GLP-1R)** agonist. GLP-1R agonist 38 can be used for the study of metabolic disorders and related diseases, including but not limited to type II diabetes mellitus (T2DM), obesity and non-alcoholic fatty liver disease (NASH) .

HY-173479

GLP-1R agonist 30	GLP Receptor	Cardiovascular Disease Metabolic Disease
GLP-1R agonist 30 is a selective and orally active GLP-1R agonist with an EC₅₀ of 0.048 nM. GLP-1R has excellent selectivity, with EC₅₀ greater than 20 μM for GLP-2R, GIPR, and GCPR. GLP-1R agonist significantly increases cAMP-stimulating activity while markedly reducing hERG inhibitory activities. GLP-1R agonist has preferable absorption and excellent β-arrestin pathway selectivity. GLP-1R agonist effectively improves glucose tolerance and promoted insulin secretion in B-hGLP1R knock-in mice .

HY-P11670

Linvixdutide	GLP Receptor	Metabolic Disease
Linvixdutide is a glucagon and **glucagon-like peptide 1 receptor (GLP-1R)** agonist with anti-obesity effects .

HY-183693

GLP-1 receptor agonist 21	GLP Receptor	Metabolic Disease
GLP-1 receptor agonist 21 is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist with an EC₅₀ of 0.64 nM. GLP-1 receptor agonist 21 reduces blood glucose levels and suppresses cumulative food consumption in diabetic mice. GLP-1 receptor agonist 21 can be used for the researches of type 2 diabetes and obesity .

HY-101116R

GLP-1R Antagonist 1 (Standard)	GCGR Reference Standards	Metabolic Disease
GLP-1R Antagonist 1 (Standard) is the analytical standard of GLP-1R Antagonist 1 (HY-101116). This product is intended for research and analytical applications. GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM .

Cat. No.	Product Name	Target	Research Area

HY-P3506

Retatrutide 3 Publications Verification LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

HY-P3506A

Retatrutide TFA 3 Publications Verification LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

HY-P10929

Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH	Drug Intermediate	Others
Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH is a drug intermediate in the synthesis of Tirzepatide. Tirzepatide is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor (GLP-1R) agonist .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting **glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R)** dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-45894

tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu Semaglutide side chain	GLP Receptor	Metabolic Disease Inflammation/Immunology
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu is an intermediate in the synthesis of the glucagon-like peptide 1 receptor (GLP-1R) agonist Semaglutide (HY-114118). tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu exhibits a strong binding affinity to albumin and can be used to modify SN38 prodrugs to improve tumor distribution .

HY-P10018

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. Bamadutide improves post-meal blood glucose control by significantly enhancing β-cell function and slowing down the rate of glucose absorption in the body. Bamadutide can be used for the research of metabolic diseases such as type 2 diabetes .

HY-P3506B

Retatrutide acetate LY3437943 acetate	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .

HY-P3539

Exendin-4 (3-39)	GCGR	Neurological Disease Endocrinology
Exendin-4 (3-39) is a *peptide. Exendin-4 (3-39) is a truncated form of Exendin-4 (HY-13443) that lacks the first two amino acids. Exendin-4 is a potent Glucagon-like* peptide-1 receptor (GLP-1r) agonist. Exendin-4 (3-39) and Exendin-4 can be used for the research of diabetic and hypothalamic-pituitary-adrenal (HPA) axis .

HY-P10302

GLP-1R/GIPR agonist-1	GLP Receptor Insulin Receptor	Metabolic Disease
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for *GLP-1* (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones *GLP-1* and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-P11043

GEP44	GLP Receptor Neuropeptide Y Receptor Arrestin	Metabolic Disease
GEP44 is a peptide biased triple agonist targeting **Glucagon-like peptide 1 receptor (GLP-1R), neuropeptide Y1 Receptor (Y1-R), and neuropeptide Y2 Receptor (Y2-R)*. GEP44 induces Y1-R antagonist-controlled, GLP-1R-dependent stimulation of insulin secretion in both rat and human pancreatic islets by counteracting effects of Y1-R and GLP-1R* agonism. GEP44 promotes insulin-independent Y1-R-mediated glucose uptake in muscle tissue and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 can be used for obesity and type 2 diabetes mellitus research .

HY-P11262

GUB021794	GLP Receptor	Metabolic Disease
GUB021794 is a potent and highly selective glucagon-like peptide-1 receptor (GLP-1R) agonist developed using the streaMLine platform with an EC₅₀ value of 18 pM. GUB021794 has a very weak activity against SCTR, with an EC₅₀ value of 190 nM. GUB021794 can significantly reduce the body weight, food intake, and total fat mass of mice in a diet-induced obesity (DIO) model. GUB021794 can be used for research on obesity/diabetes .

HY-P3542

Des His1, Glu8 Exendin-4	GCGR	Metabolic Disease
Des His1, Glu8 Exendin-4 is a potent **glucagon-like peptide-1 receptor (GLP-1-R)** antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal .

HY-P0165B

Taspoglutide acetate ITM077 acetate; R1583 acetate; BIM51077 acetate	GLP Receptor	Metabolic Disease
Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an K_i value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC₅₀ = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .

HY-P11670

Linvixdutide	GLP Receptor	Metabolic Disease
Linvixdutide is a glucagon and **glucagon-like peptide 1 receptor (GLP-1R)** agonist with anti-obesity effects .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990013

Gulgafafusp alfa Glutazumab; GMA-102; GMA-105	GCGR	Metabolic Disease
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor *GLP1R* .

Species:	Human (4) Rat (1) Mouse (2) Cynomolgus (1)
Tag:	SUMO (1) His (7) Avi (1) Myc (1) Fc (1)
Source:	HEK293 (7) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P705973

	GLP1R Protein, Cynomolgus (HEK293, His) Glucagon-Like Peptide 1 Receptor; GLP1R	Cynomolgus	HEK293

HY-P72206

	GLP1R Protein, Mouse (His-SUMO) Glp1r; Glucagon-Like Peptide 1 Receptor; GLP-1 Receptor; GLP-1-R; GLP-1R	Mouse	E. coli
	GLP1R protein, a G-protein coupled receptor, binds to GLP-1, activating adenylyl cyclase and increasing intracellular cAMP levels. This interaction regulates insulin secretion and maintains glucose homeostasis. GLP1R can also form dimers with GIPR, suggesting complex regulatory mechanisms and interactions with other receptors. GLP1R Protein, Mouse (His-SUMO) is the recombinant mouse-derived GLP1R protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag.

HY-P705621

	GLP1R Protein, Mouse (HEK293, His) Glp1r; Glucagon-Like Peptide 1 Receptor; GLP-1 Receptor; GLP-1-R; GLP-1R	Mouse	HEK293

HY-P70352

	GLP1R Protein, Human (HEK293, Fc) rHuGlucagon-Like Peptide 1 Receptor/GLP1R, Fc; Glucagon-Like Peptide 1 Receptor; GLP-1 Receptor; GLP-1-R	Human	HEK293
	The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (HEK293, Fc) is the recombinant human-derived GLP1R protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P704635

	GLP1R Protein, Human (HEK293, His) rHuGlucagon-Like Peptide 1 Receptor/GLP1R, Fc; Glucagon-Like Peptide 1 Receptor; GLP-1 Receptor; GLP-1-R	Human	HEK293
	The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (HEK293, His) is the recombinant human-derived GLP1R protein, expressed by HEK293, with C-His labeled tag.

HY-P705977

	GLP1R Protein, Rat (HEK293, His) Glucagon-Like Peptide 1 Receptor; GLP-1 Receptor; GLP-1-R; GLP-1R; Glp1r; Glpr	Rat	HEK293

HY-P705301

	GLP1R Protein, Human (Biotinylated, HEK293, His-Avi) rHuGlucagon-Like Peptide 1 Receptor/GLP1R, Fc; Glucagon-Like Peptide 1 Receptor; GLP-1 Receptor; GLP-1-R	Human	HEK293

HY-P700468

	GLP1R Protein, Human (HEK293, N-His, C-Myc) 2 Publications Verification rHuGlucagon-Like Peptide 1 Receptor/GLP1R, Fc; Glucagon-Like Peptide 1 Receptor; GLP-1 Receptor; GLP-1-R	Human	HEK293
	The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (HEK293, N-His, C-Myc) is the recombinant human-derived GLP1R protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P81160

	GLP-1R Antibody 1 Publications Verification Glucagon Like Peptide-1 Receptor; GLP 1 R; GLP 1 Receptor; GLP 1R; Glp1r; GLP; glp1r; Glucagon Like Peptide 1 Receptor; RATGL1RCP; Glip; MGC138331; GLP-1-R; GLP1R_HUMAN; Glucagon-Like Peptide 1 Receptor; GLP-1 Receptor; GLP-1-R; GLP-1R; Precursor.	WB, IHC-P, IHC-F, ICC/IF, FC	Human, Mouse, Rat
	GLP-1R Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to GLP-1R.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: